Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

Rhea-AI Summary

Biophytis SA (FP: ALBPS) has announced its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), scheduled for March 12-14 in Toulouse. This prestigious annual scientific event focuses on advancing clinical trials for frail older adults and brings together researchers, clinicians, and industry professionals.

During a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101. This treatment aims to preserve muscle and mobility in patients with obesity who are being treated with GLP-1 receptor agonists.

The ICFSR is known for its rigorous peer-review process, with all presented research being reviewed by the ICFSR Scientific Committee and published in the Journal of Frailty and Aging (JFA), a peer-reviewed publication specializing in aging and age-related diseases.

Positive

• Biophytis will present preliminary data on BIO101 for obesity-associated sarcopenia
• Participation in prestigious ICFSR conference provides scientific visibility
• Research targeting patients on GLP-1 receptor agonists addresses growing market

Negative

• None.

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company  specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse.

The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual scientific event dedicated to accelerating the development of clinical trials for frail older adults. It brings together researchers, clinicians, and industry professionals to share their experiences and advances in the prevention of frailty, disability, and dependency. All presented research undergoes a rigorous peer-review process by the ICFSR Scientific Committee and are published in the Journal of Frailty and Aging (JFA), a peer-reviewed journal specialized in aging and age-related diseases.

As part of a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101 in the preservation of muscle and mobility of patients suffering from obesity treated with GLP-1 receptor agonists.

* * * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts Biophytis
Relations Investisseurs
Investors@biophytis.com

US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242167

FAQ

What will Biophytis (ALBPS) present at the ICFSR conference in March 2025?

Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101 for preserving muscle and mobility in obesity patients treated with GLP-1 receptor agonists.

When and where is the 15th International Conference on Frailty and Sarcopenia Research that Biophytis (ALBPS) is attending?

The conference will take place from March 12 to 14, 2025, in Toulouse, France.

What is BIO101 being developed for by Biophytis (ALBPS)?

BIO101 is being developed to preserve muscle and mobility in patients with obesity who are being treated with GLP-1 receptor agonists.

How might Biophytis' (ALBPS) participation in the ICFSR conference impact its research visibility?

Participation allows Biophytis to share its research with leading experts, potentially increasing scientific credibility as all presented research undergoes peer review and publication in the Journal of Frailty and Aging.

What is the significance of Biophytis (ALBPS) targeting obesity patients on GLP-1 receptor agonists?

This targets a growing market segment, as GLP-1 agonists are increasingly prescribed for obesity but may cause muscle loss, creating a need for complementary treatments like BIO101.